Skip to main content
. 2017 Aug 2;8:182. doi: 10.3389/fendo.2017.00182

Figure 8.

Figure 8

Effect of lipoxin A4 (LXA4) on streptozotocin (STZ)-induced type 1 diabetes mellitus (type 1 DM) (A–C) and resolvin D1 on STZ-induced type 1 DM (D) [these data are taken from Ref. (137) and unpublished data]. These studies were approved by Institutional Animal Ethics committee. T1D = type 1 DM. After 7 days of acclimatization, animals received 60 ng/ml LXA4 intraperitoneally for 5 days and 45 mg/kg body weight of STZ only on day 1. (A) Plasma LXA4 levels measured on day 30 of the study. (B) Plasma glucose levels: plasma glucose estimation was performed once in 10 days until the end of the study. All values are expressed as mean ± SEM. aP ≤ 0.05 compared to 10th day control values; bP ≤ 0.05 compared to 20th day control values; cP ≤ 0.05 compared to 30th day control values; dP ≤ 0.05 compared to 10th day STZ values; eP ≤ 0.05 compared to 20th day STZ values; fP ≤ 0.05 compared to 30th day STZ values; *P ≤ 0.05 compared to untreated control; #P ≤ 0.05 compared to STZ control. All values are expressed as mean ± SEM. (C) Plasma insulin levels: plasma insulin levels were estimated on day 30. All values are expressed as mean ± SEM. *P ≤ 0.05 compared to untreated control; #P ≤ 0.05 compared to STZ. (D) Plasma glucose levels in STZ-induced type 1 DM treated with resolvin D1 (derived from DHA). *P < 0.05 compared to control.